Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

The search for an HIV prevention vaccine news

Show

From To
Optimism dominates AIDS vaccine conference

AIDS vaccine researchers, meeting in Atlanta, expressed renewed optimism that they might finally be on a path to creating a product that can prevent the deadly HIV virus.

Published
07 October 2010
From
Pridesource
Norwegian Bionor Pharma to discontinue HIV vaccine development

Norwegian company Bionor Pharma ASA said today it will not continue the development of its cell-mediated therapeutic HIV-vaccine candidate Vacc-4x as the results from the phase IIb trial with it were disappointing.

Published
01 October 2010
From
ADP News
Human Clinical Trial Of DNA-MVA HIV Vaccine Candidate Begins

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

Published
30 September 2010
From
HIV / AIDS News From Medical News Today
Genital herpes vaccine ineffective in women, study suggests

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

Published
30 September 2010
From
Science Daily
Asian efforts in AIDS vaccine development step up

Regional efforts towards an AIDS vaccine must be strengthened and harmonized, says a new article in this week's PLoS Medicine magazine.

Published
21 September 2010
From
Eurekalert Inf Dis
Elderly might not benefit from TB vaccines in development

Elderly people might not benefit from some of the tuberculosis vaccines currently in development, recent research suggests.

Published
20 September 2010
From
Eurekalert Medicine & Health
Antigenics Presents Positive, Top Line Data From Phase I Herpes Vaccine Trial

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 (HSV-2), the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

Published
29 July 2010
From
Medical News Today
Future HIV vaccines: If we build it, will they come?

On the eve of the world's biggest AIDS conference this month in Austria, a new research review shows many people wouldn't get inoculated against HIV even if a vaccine was developed.

Published
14 July 2010
From
Science Daily
Future HIV vaccines: If we build it, will they come?

On the eve of the world's biggest AIDS conference this month in Austria, a new research review shows many people wouldn't get inoculated against HIV even if a vaccine was developed.

Published
14 July 2010
From
University of Toronto
← Prev1...2526272829Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.